Mustang Bio announces its results – GuruFocus.com

Favorable safety profile, high overall response and complete response rates, and persistence of CAR T observed in patients with relapsed or refractory follicular lymphoma

The data will be presented by Dr. Mazyar Shadman of Fred Hutch

WORCESTER, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating current medical breakthroughs in cell and gene therapies into potential treatments for hematologic cancers, solid tumors and rare genetic diseases, today announced results from the follicular lymphoma (“FL”) cohort of the ongoing Phase 1/2 clinical trial of MB-106, a therapy autologous CAR T cell targeting CD20, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (“B-NHL”) and chronic lymphocytic leukemia (“CLL”) have been selected for an oral presentation at Hybrid Congress 2022 of the European Hematology Association (“EHA2022”) to be held June 9-12, 2022, both virtually and in Vienna, Austria.

The on-site presentation by Mazyar Shadman, MD, MPH, associate professor and physician at Fred Hutchinson Cancer Center (“Fred Hutch”) and the University of Washington will provide up-to-date data on FL patients beyond what is available in the summary published today on the EHA2022 website and what was presented at recent Tandem meetings. The MB-106 is developed as part of a collaboration between Mustang and Fred Hutch.

“Accepting an oral presentation at major international meetings such as EHA2022 is a prestigious achievement, and we are delighted that the Scientific Program Committee has granted Dr. Shadman this highly visible opportunity to present Fred’s compelling data. Hutch on patients with relapsed or refractory follicular lymphoma. in the ongoing Phase 1/2 clinical trial of MB-106,” said Manuel Litchman, MD, Mustang President and CEO. “Furthermore, as we present our data to more investigators at peer-reviewed meetings, we are encouraged by the enthusiasm of these investigators for the durability of responses and for the expansion of patient recruitment at Fred Hutch. with CAR T naïve follicular lymphoma to patients previously treated with CAR Ts and to patients with other CD20-positive histologies such as diffuse large B-cell lymphoma, Waldenstrom’s macroglobulinemia, and CLL. advancing its CD20-targeted CAR T cell therapy program, we look forward to planned first patient dosing in a multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed patients or refractory B-NHL and CLL under Mustang’s IND this quarter.

The details of the presentation are as follows:

Title: Efficacy and Safety of a Third Generation CD20 CART (MB-106) for the Treatment of Relapsed/Refractory Follicular Lymphoma (FL)
Session: Indolent and Mantle Cell Lymphoma
Session date and time: Saturday, June 11, 11:30 a.m. – 12:45 p.m. Central European Time
Session room: Hall C1
Abstract code: S207

For more information on EHA2022, please visit: https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/

Fred Hutch scientists were instrumental in developing these findings, and Fred Hutch and some of his scientists may benefit financially from this work in the future.

About MB-106 (CD20-targeted autologous CAR T cell therapy)
CD20 is a membrane-embedded surface molecule that plays a role in the differentiation of B cells into plasma cells. CAR T was developed by Mustang research collaborator Fred Hutch in the laboratories of the late Oliver Press, MD, Ph.D., and Brian Till, MD, associate professor in the Clinical Research Division of Fred Hutch , and under exclusive license to Mustang in 2017. The lentiviral vector drug substance used to transduce patient cells to create the MB-106 drug product produced at Fred Hutch was optimized as a third-generation CAR derived from a fully human antibody, and MB-106 is currently in an open-label phase 1/2 dose-escalation trial at Fred Hutch in patients with B-NHL and CLL. The same lentiviral vector drug substance produced at Fred Hutch will be used to transduce patient cells to create the MB-106 drug product produced at Mustang Bio’s cell processing facility in Worcester, MA, for administration as part of the Phase 1/2 multicenter clinical trial scheduled to launch shortly as part of Mustang Bio’s IND. It should be noted that Mustang Bio has made minor improvements to its cell processing to facilitate the eventual commercial launch of the product. Additionally, prior to commercial launch, Mustang Bio will replace Fred Hutch’s lentiviral vector drug substance with a vector produced by a commercial manufacturer. Additional information about the trial is available at http://www.clinicaltrials.gov using the id NCT03277729.

About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating current medical breakthroughs in cell and gene therapies into potential treatments for hematological cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to such technologies by licensing or otherwise acquiring an equity interest, fund research and development, and license or bring the technologies to market. Mustang has partnered with leading medical institutions to advance the development of CAR T therapies for multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the United States Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (FBIO). For more information, visit www.mustangbio.com.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “objective”, “intend”, “expect looking forward”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “will”, “would” and similar expressions, include, but are not limited to, any statement relating to our growth strategy and product development programs, including timing and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements regarding the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business. , no s results of operations, our financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, execute and maintain financing and strategic agreements and relationships; risks related to the results of research and development activities; risks relating to the timing of the start and completion of clinical trials; uncertainties related to preclinical and clinical trials; our reliance on third-party vendors; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulations; patents and intellectual property; competition; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K filed March 23, 2022, subsequent reports on Form 10-Q, and our other filings that we perform with the SECOND. We expressly disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except if required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company details :
Jaclyn Jaffe and Bill Begien
Mustang Bio, Inc.
(781) 652-4500
[email protected]

Contact with Investor Relations:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Contact person for media relations:
Tony Plohoros
6 degrees
(908) 591-2839
[email protected]

Mustang-Bio-Inc-.png

Comments are closed.